2014 Angiotensin Gordon Research Conference and Gordon Research Seminar

描述（由申请人提供）：肾素-血管紧张素系统（RAS）在几乎所有心血管疾病中都起着至关重要的作用，目前广泛使用阻断该系统的药物。肾素抑制剂、ACE抑制剂和血管紧张素II型1 （AT1）受体拮抗剂可分为三类，它们实质上都阻断相同的肾素-血管紧张素-AT1受体途径。尽管多年来一直认为“越封锁越好”，但最近的试验（ONTARGET， ALTITUDE）表明情况并非如此。事实上，虽然可能有更多的好处，但也有更多的副作用（低血压、高钾血症、肾功能障碍）。因此，很明显，我们已经达到了阻断这一途径所能获得的最大利益，我们需要新的途径来干预。事实上，在过去几年中，出现了多种新的RAS通路，值得探索：肾素受体（pro）、AT2受体（似乎是由血管紧张素II代谢物血管紧张素-(2-8)刺激）和ace2 -血管紧张素-(1-7)- mas受体途径。此外，血管紧张素II刺激醛固酮的合成和释放（因此该系统也被称为肾素-血管紧张素-醛固酮系统，RAAS）。醛固酮受体拮抗剂现在是治疗顽固性高血压的重要工具，与此同时，新的醛固酮受体（如GPR30）出现，醛固酮合成酶抑制剂正在作为潜在的治疗方式进行测试。第一批AT2受体（蚂蚁）激动剂目前正在临床评估中，这也适用于各种干扰ACE2-血管紧张素-(1-7)- mas受体途径的药物（例如，急性呼吸应激综合征）。显然，目前，RA(A)S领域正在迅速“超越”血管紧张素II，这是该系统的经典终产物，许多新药开始出现，也包括作用于血管紧张素II特定信号通路的药物（“偏倚AT1受体激动剂”）。血管紧张素GRC是唯一一个将这些主题集中在一起的会议。它是RAS最新发现的讨论场所，涉及基础科学家和临床医生，并结合GRS研讨会也吸引了许多来自学术界和工业界的年轻研究者。允许他们的相互作用将有助于推动该领域的发展，从而使多种新药尽快提供给患者。

DESCRIPTION (provided by applicant): The renin-angiotensin system (RAS) plays a vital role in virtually every cardiovascular disease, and drugs blocking this system are currently widely used. Three classes can be distinguished (renin inhibitors, ACE inhibitors and angiotensin II type 1 (AT1) receptor antagonists), which in essence all block the same renin- angiotensin-AT1 receptor pathway. Although for many years it was argued 'the more blockade, the better', recent trials (ONTARGET, ALTITUDE) have shown that this is not the case. In fact, at perhaps slightly more benefit, there are also more side effects (hypotension, hyperkalemia, renal dysfunction). Clearly therefore, we have reached the maximum benefit that can be obtained from blocking this pathway, and we need new pathways to interfere with. Indeed, in the last few years multiple new RAS pathways have emerged that are worth exploring: the (pro) renin receptor, the AT2 receptor (which appears to be stimulated by an angiotensin II metabolite, angiotensin-(2-8)) and the ACE2-angiotensin-(1-7)-Mas receptor pathway. In addition, angiotensin II stimulates the synthesis and release of aldosterone (hence the system is also called the renin-angiotensin- aldosterone system, RAAS). Aldosterone receptor antagonists are now important tools in resistant hypertension, whereas simultaneously new aldosterone receptors emerge (e.g., GPR30), and aldosterone synthase inhibitors are being tested as potential treatment modalities. The first AT2 receptor (ant) agonists are currently being evaluated clinically, and this is also tre for various drugs interfering with the ACE2- angiotensin-(1-7)-Mas receptor pathway (e.g., in acute respiratory stress syndrome). Clearly, at present, the RA(A)S field is rapidly moving ''beyond'' angiotensin II, the classical end-product of this system, and many new drugs start to emerge, also including drugs that acts on one specific signaling pathway of angiotensin II (''biased AT1 receptor agonists''). The Angiotensin GRC is the only meeting where these topics come together in one meeting. It is THE discussion place for the latest discoveries in the RAS, involving basic scientists and clinicians, and combined with a GRS Seminar also attracts a lot of young investigators from academia and industry. Allowing their interaction will help to move the field forward, thus making multiple new drugs available to patients ASAP.